Document Detail

Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature.
MedLine Citation:
PMID:  19940453     Owner:  NLM     Status:  MEDLINE    
Published experiences of TNF-alpha inhibition during pregnancy consist of a limited number of case reports, series and ongoing registry data in patients with arthritis and inflammatory bowel disease. A 28-year-old woman - with psoriasis vulgaris since she was 8 years of age and generalized pustular psoriasis during her first pregnancy (partially controlled with ciclosporin, oral prednisone and topical corticosteroids, when lupus anticoagulant was detected at another hospital) - presented 4 months after delivery with severe psoriasis (PASI = 15.4) that did not respond to ciclosporin (3 mg/kg/day). Ten days after the first infusion of infliximab (5 mg/kg), when the patient became aware that she was pregnant again, there was PASI75 response, and the patient wished to continue this treatment after being fully informed. Complete blanching was achieved by week 6 of treatment, and was maintained thereafter until the moment of writing (19 months after the start of treatment). She gave birth by caesarean delivery to a healthy female baby, who was breastfed for 1 month and has developed normally. The current report extends the available evidence on successful infliximab treatment in pregnant women, with the first case of a patient with psoriasis who presented impetigo herpetiformis during her previous pregnancy. No detectable adverse effects were detected in the neonate, despite potential exposure to infliximab throughout gestation and breastfeeding. Even though absolute safety is difficult to prove, available data suggest that women who become pregnant while taking infliximab or other anti-TNFalpha agents can be reassured regarding the continuation of pregnancy.
Llu?s Puig; Didac Barco; Agust?n Alomar
Related Documents :
2254903 - Severe cerebral and systemic necrotizing vasculitis developing during pregnancy in a ca...
20701473 - Lupus nephritis mimicking pyelonephritis in pregnancy.
16706323 - Maternal diabetes and perinatal outcomes in west virginia medicaid enrollees.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2009-11-25
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  220     ISSN:  1421-9832     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2010  
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-04-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  71-6     Citation Subset:  IM    
Copyright Information:
Copyright 2009 S. Karger AG, Basel.
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Aut?noma de Barcelona, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Cyclosporine / therapeutic use
Infant, Newborn
Pregnancy Complications / drug therapy*
Psoriasis / drug therapy*
Treatment Outcome
Tumor Necrosis Factors / antagonists & inhibitors*
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antibodies, Monoclonal; 0/Tumor Necrosis Factors; 0/infliximab; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of Genes for Appetite-Regulating Peptides in the Hypothalamus of Genetically Selected Lea...
Next Document:  Procalcitonin: inflammatory biomarker for assessing the severity of community-acquired pneumonia--a ...